The Role of Mutation in Cancer Cell Growth

Helal Marwa^*
*Correspondence: Helal Marwa, Department of Biology, University of Southern Denmark, 5230 Odense, Denmark, Email:

Introduction

Mutations are a central feature of cancer and play a critical role in the initiation, progression, and eventual malignancy of tumors. Cancer, in its essence, is a disease of the genome, driven by genetic alterations that confer a growth advantage to cells. The genetic changes that occur in cancer are typically mutations alterations in the DNA sequence of genes that disrupt normal cellular functions. These mutations can be inherited, but more often they arise sporadically during a person’s lifetime, due to a combination of genetic predispositions and environmental factors. Understanding the role of mutation in cancer cell growth is crucial for deciphering how cancers develop and evolve, and for developing more effective treatments.

Description

The human genome consists of approximately 3 billion base pairs of DNA, encoding a vast array of proteins that govern cellular functions such as cell division, repair, and apoptosis (programmed cell death). In normal cells, the complex regulatory networks that control these processes ensure that growth is tightly regulated. However, in cancer cells, mutations accumulate in key genes that control these processes, resulting in uncontrolled cell division and survival. These mutations may affect a variety of genes, including oncogenes, tumor suppressor genes, and genes involved in DNA repair. Oncogenes are genes that, when mutated or overexpressed, promote cancerous growth. They typically encode proteins that stimulate cell division or inhibit cell death. Under normal circumstances, these genes are tightly regulated, but mutations can lead to their constant activation [1,2].

For instance, the RAS gene, which encodes a GTPase involved in signalling pathways that regulate cell proliferation, is frequently mutated in various cancers. Mutations in RAS can result in the continuous activation of downstream signalling pathways, leading to unregulated cell growth and survival. Similarly, mutations in other oncogenes, such as MYC, BRAF, or EGFR, contribute to the malignant transformation of normal cells. In contrast to oncogenes, tumor suppressor genes are responsible for inhibiting cell growth and promoting the repair or elimination of damaged cells. When these genes are mutated or lost, cells lose critical checkpoints that would normally halt division or induce cell death in the presence of DNA damage [3].

Other important tumor suppressor genes include BRCA1 and BRCA2, which are involved in the repair of double-strand breaks in DNA. Mutations in these genes predispose individuals to breast and ovarian cancers. The loss of function of BRCA1/2 impairs the DNA repair process, allowing additional mutations to accumulate, which accelerates the development of cancer. In fact, the role of DNA repair genes in cancer is particularly significant because errors in DNA replication and repair are a primary source of the mutations that drive cancer cell growth. Mutations can also occur in genes that regulate the cell cycle, a tightly orchestrated process that ensures proper cell division. The Cyclin-Dependent Kinases (CDKs) and cycling, which regulate the progression of the cell cycle, can be altered in cancer cells to promote uncontrolled proliferation.

Genetic mutations also play a significant role in the ability of cancer cells to evade the immune system. The immune system plays a crucial role in identifying and eliminating abnormal cells, including those with mutations. However, cancer cells can acquire mutations that allow them to escape immune surveillance. For example, mutations in genes involved in antigen presentation, such as the Major Histocompatibility Complex (MHC) class I genes, can render tumor cells invisible to T cells, the immune cells responsible for recognizing and destroying abnormal cells. Additionally, mutations in immune checkpoint genes, such as PD-1 and CTLA-4, can enhance the ability of cancer cells to avoid immune detection, leading to immune evasion. Mutations also contribute to the ability of cancer cells to promote angiogenesis, the formation of new blood vessels that supply the growing tumor with oxygen and nutrients. Angiogenesis is regulated by a delicate balance of pro-angiogenic and anti-angiogenic signals [4].

As tumors grow, they often become more genetically heterogeneous. This heterogeneity arises because cancer cells are prone to accumulate mutations at a higher rate than normal cells. The process of tumor evolution is driven by mutations that confer a selective advantage, allowing some clones of cancer cells to outgrow others. This dynamic process can lead to the emergence of subpopulations of tumor cells with distinct mutations, some of which may allow them to invade surrounding tissues, resist chemotherapy, or metastasize to distant organs. This genetic diversity within a tumor is a major challenge in cancer treatment, as different subclones of tumor cells may respond differently to therapies. In fact, the clonal evolution of tumors is a driving force behind therapeutic resistance, making it more difficult to achieve durable remissions [5].

The advent of targeted therapies, which are designed to specifically inhibit the activity of mutated oncogenes or other key proteins involved in cancer cell survival, has transformed the treatment landscape for some cancers. For instance, small molecule inhibitors that target the mutant BRAF protein have shown great promise in the treatment of melanoma and other cancers. Similarly, monoclonal antibodies that target the epidermal growth factor receptor (EGFR) have been used to treat lung cancers with EGFR mutations. While these therapies can be highly effective in some patients, resistance often develops as cancer cells acquire additional mutations that enable them to bypass the inhibited signaling pathway. This underscores the importance of understanding the role of mutation not only in the initiation of cancer but also in its evolution during treatment.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Cruz, Rebecca, Lee Hedden, Derek Boyer and Michael G. Kharas, et al. "S6 kinase 2 potentiates interleukin-3-driven cell proliferation." J Leukoc Biol 78 (2005): 1378-1385.

Google Scholar, Crossref, Indexed at

2. Rossi, Rossella, John M. Pester, Mitch McDowell and Samuela Soza, et al. "Identification of S6K2 as a centrosome-located kinase." FEBS Lett 581 (2007): 4058-4064.

Google Scholar, Crossref, Indexed at

3. Savinska, Lilia, Oleksandr Skorokhod, Olga Klipa and Ivan Gout, et al. "Development of monoclonal antibodies specific to ribosomal protein S6 kinase 2." Hybridoma 31 (2012): 289-294.

Google Scholar, Crossref, Indexed at

4. Basu, Alakananda and Savitha Sridharan. "Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2." PLoS ONE 12 (2017): e0173854.

Google Scholar, Crossref, Indexed at

5. Saxton, Robert A. and David M. Sabatini. "mTOR signaling in growth, metabolism, and disease." Cell 168 (2017): 960-976.

Google Scholar, Crossref, Indexed at